Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors - 2017
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors - 2016
Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator - 2016
Pharmacological Targeting of Kinases MST1 and MST2 Augments Tissue Repair and Regeneration - 2016
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer - 2013
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors - 2010
Targeting cancer with small molecule kinase inhibitors - 2009
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M - 2009
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity - 2007
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics - 2007

RedCloud Bio focuses on novel targets or known targets with drug resistance, integrating structural pharmacology and computational technologies, to discover and develop breakthrough therapeutics for patients with cancer and other severe diseases of high unmet needs.

Create Medicines With Unprecedented Precision

For Healthier Life.

﹀

——————

An Innovative, Proprietary Discovery And Development Platform


RedCloud Bio has established a robust small molecule drug discovery engine based on experimental structural pharmacology and enhanced by molecular dynamics simulations, computational chemistry and artificial intelligence, and a dedicated and experienced preclinical and clinical development team. Focusing on new and known drug targets with high unmet medical needs…

>
More Information

Breakthrough Technologies In Structural Pharmacology


Our structural pharmacology approach enables us to gain precise, detailed insights into molecular structures and mechanisms of action of critical mutations – a crucial step for rational design and advancement of new drugs. RedCloud Bio has integrated ultra-high-throughput virtual screening (UHTVS) algorithms and molecular dynamics/ computational chemistry-aided compound optimization to facilitate discovery and development of novel small molecule drugs with specificity and efficiency.
>
More Information

Innovative Discovery And Clinical Pipeline


RedCloud Bio has accumulated structural data and algorithm

models covering clinically important targets, and has built an innovative pipeline targeting tumor resistance, rare and other critical diseases with high unmet medical needs, using its core technology platform.

The Company’s lead therapeutic candidate, H002, is a small molecule compound addressing EGFR activating mutations, and is expected to enter global clinical trials. The compound is a promising candidate as a next-generation TKI with unique clinical differentiation for NSCLC.

>
More Information

Competitive Research And Development Teams


RedCloud Bio has built laboratories in Shanghai and Beijing, with discovery and development teams covering structural pharmacology, computational technologies, medicinal chemistry and biology as well as disciplines related to preclinical and clinical development and chemistry, manufacturing and controls.

>
More Information
Publications
Your ability to access these articles may depend on your or your institution's subscriptions to the journals.
Contact Us

 

Nanjing   ｜307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District Shanghai｜Suite 901, 880 Xiangyang Road, Minhang District Beijing   ｜Suite 205, Building No.2, PKUCare Industrial Park, Changping District Website: https://www.redcloudbio.com

Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved